Serum glial fibrillary acidic protein
Serum glial fibrillary acidic protein
Overview
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein expressed predominantly by astrocytes in the central nervous system (CNS). It serves as a structural component of the astrocytic cytoskeleton and plays a fundamental role in maintaining cellular integrity, supporting myelination, and mediating responses to CNS injury. When astrocytes are damaged, stressed, or undergo reactive gliosis, GFAP is released into the extracellular space and subsequently enters the bloodstream, making serum and plasma GFAP (sGFAP) a measurable surrogate of astrocytic injury and neurodegeneration. Its elevation in peripheral blood reflects diverse CNS pathologies, ranging from acute traumatic brain injury to chronic neurodegenerative and neuroinflammatory diseases.
As a fluid biomarker, sGFAP has attracted substantial interest due to advances in ultrasensitive immunoassay platforms that enable reliable quantification at sub-picogram-per-milliliter concentrations in blood. Unlike invasive cerebrospinal fluid sampling, blood-based GFAP measurement offers a practical, scalable approach for disease monitoring, prognostication, and therapeutic response assessment. Its utility spans multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (mTBI), epilepsy, HIV-associated neurocognitive disorders, and aging-related cognitive decline, positioning sGFAP as one of the most broadly applicable CNS biomarkers in contemporary translational neuroscience.
Focus of Latest Publications
Recent investigations demonstrate serum glial fibrillary acidic protein (sGFAP) as a sensitive biomarker reflecting astrocytic activation and neuroinflammation across acute and chronic central nervous system pathology. Studies evaluated sGFAP across acute traumatic and ischemic brain injury, progressive neurological conditions including multiple sclerosis and amyotrophic lateral sclerosis, and neurodegenerative diseases such as Alzheimer's disease. Research employed diverse immunoassay platforms including traditional laboratory-based methods, automated chemiluminescent systems, and point-of-care nanophotonic biosensors integrated with artificial intelligence-assisted analysis, enabling quantification in serum, plasma, and capillary blood samples for diagnostic and prognostic applications.
In acute brain injury, sGFAP shows clinical promise for both diagnostic exclusion and prognostic stratification. In mild traumatic brain injury, serum GFAP combined with ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1), measured within 12 hours of injury, effectively ruled out computed tomography-detectable intracranial lesions in emergency department populations, with potential to reduce unnecessary neuroimaging and radiation exposure. In acute ischemic stroke cohorts, serum GFAP levels were significantly elevated compared to controls with a characteristic temporal pattern peaking at 48–72 hours post-symptom onset. Elevated admission GFAP concentrations independently predicted poor functional outcomes at three months and shorter long-term survival, and elevated levels correlated with hemorrhagic transformation and systemic infection complications including pneumonia.
In chronic progressive neurological conditions, sGFAP tracks astrocytic activation related to disease progression and comorbidities. Multiple sclerosis studies demonstrated that sGFAP remained stable during immunotherapy transitions from intravenous to subcutaneous natalizumab, supporting continuity of CNS injury monitoring during treatment changes. Serum GFAP in combination with retinal structural markers from optical coherence tomography provided additive prognostic value for predicting disability progression independent of clinical relapse activity. In amyotrophic lateral sclerosis, plasma GFAP defined a distinct biological axis characterized primarily by association with age and behavioral lability, complementing neurofilament light chain (reflecting upper motor neuron burden) and phosphorylated tau-181 (reflecting lower motor neuron degeneration). In Alzheimer's disease and related cognitive impairment, sGFAP correlated with cognitive performance and functional status, and capillary blood self-collection methods now enable point-of-care screening to triage individuals at varying risk of cognitive decline in community settings.
Beyond individual conditions, evidence supports GFAP's utility as a complementary biomarker integrated with other CNS injury markers. In temporal lobe epilepsy, sGFAP levels were elevated in patients with comorbid depression compared to those with epilepsy alone, suggesting astroglial activation linked to psychiatric comorbidity. In acute ischemic stroke, multiplex biomarker panels incorporating GFAP, S100B, and UCH-L1 achieved improved diagnostic accuracy for differentiating stroke subtypes. Technical advances including nanophotonic heterochain biosensors with deep learning-integrated image analysis, portable smartphone-based detection platforms, and fully automated chemiluminescent immunoassays have enhanced assay sensitivity and accessibility. Standardized preanalytical handling protocols and reference ranges in healthy adult populations have been established, supporting integration of GFAP testing into evidence-based clinical pathways for emergency and outpatient management of acute and chronic CNS conditions.